Trade

with

Alnylam Pharmaceuticals Inc
(NASDAQ: ALNY)
AdChoices
89.48
+0.54
+0.61%
After Hours :
-
-
-

Open

88.97

Previous Close

88.94

Volume (Avg)

112.59k (685.78k)

Day's Range

87.05-89.97

52Wk Range

47.03-112.57

Market Cap.

6.79B

Dividend Rate ( Yield )

-

Beta

1.65

Shares Outstanding

76.35M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 47.17M

    • Net Income

    • -89.22M

    • Market Cap.

    • 6.79B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -1,008.42

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.65

    • Forward P/E

    • -40.16

    • Price/Sales

    • 169.49

    • Price/Book Value

    • 7.20

    • Price/Cash flow

    • -43.86

      • EBITDA

      • -82.71M

      • Return on Capital %

      • -47.76

      • Return on Equity %

      • -57.11

      • Return on Assets %

      • -47.76

      • Book Value/Share

      • 12.34

      • Shares Outstanding

      • 76.35M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Outperform
        • 1 Year Price Target

        • 108.00

        • Credit Rating

        • -

        • Analysts

        • 2

        • EPS Estimate

        • -2.57

        • Cashflow Estimate

        • -1.72

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -16.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -13.28

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -1,057.65

            • 39.38

            • Net Profit Margin

            • -1,008.42

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -105.80

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -101.70

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 12.38

              • 2.92

              • Quick Ratio

              • 12.18

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.10

              • 2.21

              • Book Value/Share

              • 12.34

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -16.23

                • 196.08

                • P/E Ratio 5-Year High

                • -21.20

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.11

                • 124.82

                • Price/Sales Ratio

                • 163.93

                • 9.12

                • Price/Book Value

                • 6.98

                • 8.26

                • Price/Cash Flow Ratio

                • -43.86

                • 47.39

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -57.11

                    (-44.20)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -47.76

                    (-19.70)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -57.11

                    (-44.20)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.05

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -92.94M
                  Operating Margin
                  -197.05
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -43.86
                  Ownership

                  Institutional Ownership

                  91.22%

                  Top 10 Institutions

                  61.26%

                  Mutual Fund Ownership

                  54.66%

                  Float

                  63.55%

                  5% / Insider Ownership

                  0.29%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Growth Company Fund

                  •  

                    5,148,491

                  • 1.17

                  • 6.74

                  • Vanguard Health Care Fund

                  •  

                    4,973,900

                  • 9.93

                  • 6.52

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    1,660,245

                  • 0.76

                  • 2.17

                  • Fidelity® Series Growth Company Fund

                  •  

                    1,226,826

                  • 1.17

                  • 1.61

                  • Vanguard Small Cap Index

                  •  

                    1,061,036

                  • 7.43

                  • 1.39

                  • Vanguard Total Stock Mkt Idx

                  •  

                    1,026,135

                  • 11.37

                  • 1.34

                  • iShares Nasdaq Biotechnology

                  •  

                    1,012,441

                  • -0.69

                  • 1.49

                  • T. Rowe Price Mid Cap Growth Fund

                  •  

                    1,000,000

                  • 0.00

                  • 1.31

                  • VA CollegeAmerica Small Cap World

                  •  

                    848,700

                  • 0.00

                  • 1.11

                  • Prudential Jennison Health Sciences

                  •  

                    787,111

                  • 0.00

                  • 1.03

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    11,284,108

                  • +17.86%

                  • 14.78

                  • Wellington Management Company, LLP

                  •  

                    9,132,117

                  • +13.52%

                  • 11.96

                  • Vanguard Group, Inc.

                  •  

                    3,276,926

                  • +22.20%

                  • 4.29

                  • T. Rowe Price Associates, Inc.

                  •  

                    3,252,033

                  • -9.53%

                  • 4.26

                  • Franklin Advisers, Inc.

                  •  

                    2,538,728

                  • -2.32%

                  • 3.33

                  • Gilder Gagnon Howe & CO LLC

                  •  

                    1,995,870

                  • +4.19%

                  • 2.61

                  • Novartis AG

                  •  

                    1,697,691

                  • -58.09%

                  • 2.66

                  • BlackRock Fund Advisors

                  •  

                    1,597,915

                  • +4.65%

                  • 2.09

                  • Baillie Gifford & Co Limited.

                  •  

                    1,190,930

                  • +11.01%

                  • 1.56

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Mid Growth

                  Alnylam Pharmaceuticals Inc is a Delaware corporation that was formed in May 2003. The Company is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological ...morepathway within cells for selectively silencing and regulating the expression of specific genes. The Companys core product Alnylam 5x15, was launched in January 2011 and is focused on the development and commercialization of novel RNAi therapeutics as genetic medicines. Its genetic medicine programs are RNAi therapeutics directed towards genetically defined targets for the treatment of diseases with high unmet medical need. The Company is currently advancing the following core programs in clinical or pre-clinical development: patisiran (the International Nonproprietary Na...moreme for ALN-TTR02), an intravenously delivered RNAi therapeutic targeting transthyretin, or TTR, in development for the treatment of TTR-mediated amyloidosis, or ATTR, in patients with familial amyloidotic polyneuropathy, or FAP; ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting TTR in development for the treatment of ATTR in patients with TTR cardiac amyloidosis, including familial amyloidotic cardiomyopathy, or FAC, and senile systemic amyloidosis, or SSA; ALN-AT3, an RNAi therapeutic targeting antithrombin, or AT, in development for the treatment of hemophilia and rare bleeding disorders, or RBD; ALN-CC5, an RNAi therapeutic targeting complement component C5 in development for the treatment of complement-mediated diseases; ALN-AS1, an RNAi therapeutic targeting aminolevulinate synthase-1, or ALAS-1, in development for the treatment of hepatic porphyrias, including acute intermittent porphyria, or AIP; ALN-PCSsc, an RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9, or PCSK9, in development for the treatment of hypercholesterolemia; ALN-AAT, an RNAi therapeutic targeting alpha-1-antitrypsin, or AAT, in development for the treatment of AAT deficiency liver disease; ALN-TMP, an RNAi therapeutic targeting transmembrane protease, serine 6, or TMPRSS6, in development for the treatment of beta-thalassemia and iron-overload disorders; ALN-ANG, an RNAi therapeutic targeting angioprotein-like 3, or ANGPTL3, in development for the treatment of genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia; and other yet to be disclosed programs. The Companys product platform provides a capability for an approach to identifying RNAi therapeutic product candidates through sequence selection, potency selection, stabilization by chemical modification, improvement of biodistribution and cellular uptake by various chemical conjugates and formulations. Its competitors include Novartis, Takeda, Kyowa Hakko Kirin, Marina Biotech, Inc., Arrowhead and its subsidiary, Calando, Quark, Silence Therapeutics plc, Tekmira, Sylentis and Dicerna Pharmaceuticals, Inc., Regulus, Rosetta Genomics, Santaris Pharma A/S, or Santaris, miRagen Therapeutics, Inc., Mirna Therapeutics, Inc. and Asuragen, Inc. The research, testing, manufacture and marketing of drug products and their delivery systems are extensively regulated in the United States and the rest of the world.lessless

                  Key People

                  Dr. John M. Maraganore,PhD

                  CEO/Director/Founder

                  John K. Clarke

                  Chairman of the Board/Director/Founder

                  Mr. Michael P. Mason

                  CFO/Chief Accounting Officer/Treasurer/Vice President, Divisional

                  Dr. Akshay K. Vaishnaw,M.D.,Ph.

                  Chief Medical Officer/Executive VP

                  Marsha H. Fanucci

                  Director

                  • Alnylam Pharmaceuticals Inc

                  • 300 Third Street

                  • Cambridge, MA 02142

                  • USA.Map

                  • Phone: +1 617 551-8200

                  • Fax: +1 617 551-8101

                  • alnylam.com

                  Incorporated

                  2003

                  Employees

                  165

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: